Literature DB >> 15336969

Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy.

Kobra Haghighi1, Kimberly N Gregory, Evangelia G Kranias.   

Abstract

Dilated cardiomyopathy is a disease of the heart muscle resulting from a diverse array of conditions that damages the heart and impairs myocardial function. Heart failure occurs when the heart is unable to pump blood at a rate which can accommodate the heart muscle's metabolic requirements. Several signaling pathways have been shown to be involved in the induction of cardiac disease and heart failure. Many of these pathways are linked to cardiac sarcoplasmic reticulum (SR) Ca cycling directly or indirectly. A large body of evidence points to the central role of abnormal Ca handling by SR proteins, Ca-ATPase pump (SERCA2a) and phospholamban (PLN), in pathophysiological heart conditions, compromising the contractile state of the cardiomyocytes. This review summarizes studies which highlight the key role of these two SR proteins in the regulation of cardiac function, the significance of SERCA2a-PLN interactions using transgenic approaches, and the recent discoveries of human PLN mutations leading to disease states. Finally, we will discuss extrapolation of experimental paradigms generated in animal models to the human condition. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336969     DOI: 10.1016/j.bbrc.2004.07.164

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

2.  Structure, dynamics, and ion conductance of the phospholamban pentamer.

Authors:  Christopher Maffeo; Aleksei Aksimentiev
Journal:  Biophys J       Date:  2009-06-17       Impact factor: 4.033

Review 3.  Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.

Authors:  Changwon Kho; Ahyoung Lee; Roger J Hajjar
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

4.  Abnormal termination of Ca2+ release is a common defect of RyR2 mutations associated with cardiomyopathies.

Authors:  Yijun Tang; Xixi Tian; Ruiwu Wang; Michael Fill; S R Wayne Chen
Journal:  Circ Res       Date:  2012-02-28       Impact factor: 17.367

Review 5.  Treating heart failure with cardiac contractility modulation electrical signals.

Authors:  Hani N Sabbah; Ramesh C Gupta; Sharad Rastogi; Sudhish Mishra; Yuval Mika; Daniel Burkhoff
Journal:  Curr Heart Fail Rep       Date:  2006-04

6.  Myostatin regulates tissue potency and cardiac calcium-handling proteins.

Authors:  Melissa F Jackson; Naisi Li; Buel D Rodgers
Journal:  Endocrinology       Date:  2014-02-11       Impact factor: 4.736

7.  Tuning the structural coupling between the transmembrane and cytoplasmic domains of phospholamban to control sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) function.

Authors:  Kim N Ha; Martin Gustavsson; Gianluigi Veglia
Journal:  J Muscle Res Cell Motil       Date:  2012-09-13       Impact factor: 2.698

8.  Refilling Intracellular Calcium Stores.

Authors:  Changwon Kho; Ahyoung Lee; Dongtak Jeong; Roger J Hajjar
Journal:  Drug Discov Today Dis Mech       Date:  2010

Review 9.  Phospholamban and sarcolipin: Are they functionally redundant or distinct regulators of the Sarco(Endo)Plasmic Reticulum Calcium ATPase?

Authors:  Sana A Shaikh; Sanjaya K Sahoo; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2015-12-29       Impact factor: 5.000

10.  No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure.

Authors:  Diogo G B Santos; Alessandra Medeiros; Patrícia C Brum; José G Mill; Alfredo J Mansur; José E Krieger; Alexandre C Pereira
Journal:  BMC Cardiovasc Disord       Date:  2009-07-28       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.